首页> 外文期刊>American Journal of Blood Research >Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)
【24h】

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)

机译:疑似系统性肥大细胞增多症患者的指南和诊断算法:奥地利能力网络(AUCNM)的建议

获取原文
获取外文期刊封面目录资料

摘要

Systemic mastocytosis (SM) is a hematopoietic neoplasm characterized by pathologic expansion of tissue mast cells in one or more extracutaneous organs. In most children and most adult patients, skin involvement is found. Childhood patients frequently suffer from cutaneous mastocytosis without systemic involvement, whereas most adult patients are diagnosed as suffering from SM. In a smaller subset of patients, SM without skin lesions develops which is a diagnostic challenge. In the current article, a diagnostic algorithm for patients with suspected SM is proposed. In adult patients with skin lesions and histologically confirmed mastocytosis in the skin (MIS), a bone marrow biopsy is recommended regardless of the serum tryptase level. In adult patients without skin lesions who are suffering from typical mediator-related symptoms, the basal serum tryptase level is an important diagnostic parameter. In those with slightly elevated tryptase (15-30 ng/ml), additional non-invasive investigations, including a emKIT/em mutation analysis of peripheral blood cells and sonographic analysis, is performed. In adult patients in whom i) KIT D816V is detected or/and ii) the basal serum tryptase level is clearly elevated (> 30 ng/ml) or/and iii) other clinical or laboratory features are suggesting the presence of occult mastocytosis, a bone marrow biopsy should be performed. In the absence of emKIT/em D816V and other indications of mastocytosis, no bone marrow investigation is required, but the patient’s course and the serum tryptase levels are examined in the follow-up.
机译:系统性肥大细胞增多症(SM)是一种造血性肿瘤,其特征在于一个或多个皮外器官中组织肥大细胞的病理性扩张。在大多数儿童和大多数成年患者中,发现皮肤受累。儿童患者经常患有皮肤肥大细胞增多症而没有全身性受累,而大多数成年患者被诊断为患有SM。在较小部分的患者中,发展为无皮肤损害的SM,这是诊断上的挑战。在当前的文章中,提出了一种针对可疑SM患者的诊断算法。对于有皮肤病变且经组织学确认为皮肤肥大细胞增多(MIS)的成年患者,无论血清类胰蛋白酶水平如何,均建议进行骨髓活检。在没有皮肤病变的成年患者中,患有典型的与介质相关的症状的患者,基础血清类胰蛋白酶水平是重要的诊断参数。对于胰蛋白酶稍微升高(15-30 ng / ml)的患者,还进行了其他非侵入性研究,包括外周血细胞的 KIT 突变分析和超声检查。在i)检测到KIT D816V或/和ii)基础血清类胰蛋白酶水平明显升高(> 30 ng / ml)或/和iii)其他临床或实验室特征表明存在隐匿性的成年患者中肥大细胞增多症,应进行骨髓活检。在没有 KIT D816V和肥大细胞增多症的其他指征的情况下,不需要进行骨髓检查,但是在随访中检查了患者的病程和血清类胰蛋白酶水平。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号